secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001193125-26-139145
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split
--------------------------------------------------------------------------------

- Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.
- Reverse stock split effective March 6, 2026, to cure bid price deficiency below $1.00.
- Company subject to Mandatory Panel Monitor until March 31, 2027; future non-compliance may trigger delisting.
- Hearings Panel granted exception until March 20, 2026; compliance achieved with 10 consecutive days above $1.00.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/0001193125-26-139145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/dcoy-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-139145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer